Is lasting remission feasible in the real-world setting? No!
This article summarises a debate at the 59th EASD Annual Meeting 2-6 October 2023, Hamburg, Germany at which Professor Khunti spoke against the motion and Professor Taylor spoke for the motion
DOI:
https://doi.org/10.15277/bjd.2024.453Keywords:
type 2 diabetes, T2DM, remission, LCDReferences
Captieux M, Prigge R, Wild S, Guthrie B. Defining remission of type 2 diabetes in research studies: a systematic scoping review. PLoS Med 2020;17(10):e1003396. https://doi.org/10.1371/journal.pmed.1003396
Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care 2021;44(10):2438-44. https://doi.org/10.2337/dci21-0034
Gregg EW, Zhang P, Li G, Engelgau MM, Bennett PH. Cardiovascular outcomes in the DA Qing Diabetes Prevention study. Lancet 2008; 371:1783-89.
Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care- led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster- randomised trial. Lancet Diabetes Endocrinol 2019;7(5):344-55. https://doi.org/10.1016/S2213-8587(19)30068-3
Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013; 369(2):145-54. https://doi.org/10.1056/NEJMoa1212914
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo- controlled, phase 3 trial. Lancet 2023;402(10402):613-26. https://doi.org/10.1016/S0140-6736(23)01200-X
Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo- controlled, phase 3 trial. Lancet 2021;397(10278):971-84. https://doi.org/10.1016/S0140-6737(21)00213-0
Sjostrom L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA 2014; 311(22):2297-304. https://doi.org/10.1001/jama.2014.5988
Holman N, Wild SH, Khunti K, et al. Incidence and characteristics of remission of type 2 diabetes in England: a cohort study using the National Diabetes Audit. Diabetes Care 2022;45(5):1151-61. https://doi.org/10.2337/dc21-2136
Holman N, Khunti K, Wild SH, et al. Care processes in people in remission from type 2 diabetes: a cohort study using the National Diabetes Audit. Diabet Med 2023;40(3):e15016. https://doi.org/10.1111/dme.15016
Falkentoft AC, Gerds TA, Zareini B, et al. Risk of first-time major cardiovascular event among individuals with newly diagnosed type 2 diabetes: data from Danish registers. Diabetologia 2023;66(11):2017-29. https://doi.org/10.1007/s00125-023-05977-6
Svedbo Engstrom M, Leksell J, Johansson UB, Gudbjornsdottir S. What is important for you? A qualitative interview study of living with diabetes and experiences of diabetes care to establish a basis for a tailored Patient-Reported Outcome Measure for the Swedish National Diabetes Register. BMJ Open 2016;6(3):e010249. https://doi.org/10.1136/bmjopen-2015-010249
Published
Issue
Section
License
Copyright (c) 2024 British Journal of Diabetes
This work is licensed under a Creative Commons Attribution 4.0 International License.
Publish & Transfer of Copyright Agreement
For the mutual benefit and protection of the Author and the Journal Owner/Publisher it is necessary that the Author provides formal written Consent to Publish and Transfer of Copyright before publication of the Work.
